Skylar Jeremias

Patient selection raised detection of pathogenic germline variants from 6% to 27% in lung cancer studies.

Erythema-based criteria miss skin of color, urging ROSCO phenotyping to improve diagnostic equity in dermatology.

Mayo Clinic case-control study links higher birth weight and childhood obesity to greater non-Hodgkin lymphoma risk, while longer breastfeeding may lower odds.

Two machine learning models identifies MASLD in lean adults using 8 routine clinical measurements.

Meta-analysis suggests off-label upadacitinib drives major alopecia areata hair regrowth and SALT score gains, but phase 3 trials show lower responses.

Nearly half of patients with chronic HBV or HCV also had MASLD, tied to worse fatigue and quality of life.

Reductions in antibody function, not IgG titers, distinguishes efgartigimod responders in myasthenia gravis.

Availity's founding CEO on what early payer connectivity teaches about price transparency.

Asia-Pacific Delphi Consensus updates alopecia areata clinical guidelines for trichoscopy, SALT Score severity, and first-line JAK inhibitors.

Deep learning digital pathology predicts mantle cell lymphoma outcomes from routine biopsy slides, matching biomarkers to improve MIPI risk stratification.

Asian expert consensus updates mantle cell lymphoma treatment guidelines, highlighting uneven BTK inhibitor, ibrutinib and CAR T-cell access across Asia.

Dallas population health roundtable exposes prior authorization hurdles, ICD coding gaps, and copay barriers delaying care coordination.

Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.

Off-the-shelf CTX110 allogeneic CD19 CAR T shows responses in relapsed/refractory B-cell lymphoma, with manageable cytokine release syndrome.

A real-world trial found 42.6% of patients with severe hand eczema cleared on oral alitretinoin.

An international eDelphi panel of 62 dermatologists agreed on a 2-step algorithm for tapering psoriasis biologics.

Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.

Non-Hodgkin lymphoma mortality trends impact lower-income, less-educated communities, highlighting health disparities and needs for health equity.

Cleveland roundtable panelists across 4 disease states name access, not evidence, as the shared barrier to care.

Subcutaneous mosunetuzumab plus polatuzumab vedotin boosts responses in relapsed large B-cell lymphoma, helping community oncology care.

Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.

A 39,669-patient French cohort found ustekinumab and IL-23 inhibitors carry the lowest infection risk among biologics.

This analysis in RR MCL shows CAR T-cell therapy (brexucabtagene) yields higher complete responses vs bispecific antibodies; durability remains unclear.

Meta-analysis finds oral JAK inhibitors like baricitinib and ritlecitinib drive strong alopecia areata hair regrowth, improving SALT scores with manageable safety.

Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.

In HIV, lymphoma survival tracks tumor stage and CD4 count, not viral suppression, a Spanish cohort shows.

Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.

Wet work harms the skin barrier and microbiome as delgocitinib emerges.

A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.

A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.